Taylor S A
University of Kansas Medical Center, Kansas City.
J Neurooncol. 1994;20(2):141-53. doi: 10.1007/BF01052724.
A review of single agent trials of cytotoxic agents in adults with high grade gliomas is presented. The rationale for testing these agents in patients with brain tumors was variable and is discussed. The criteria to evaluate responses were also variable ranging from subjective evaluation of clinical improvement with a stable radiographic assessment to the same objective response criteria utilized for solid tumors. Trials of agents specifically designed for brain tumors such as AZQ and spiromustine have been disappointing. There are encouraging results being seen in early trials of newer agents which await confirmation in larger trials but which hold promise for improving the disappointing results seen so far with chemotherapy in primary brain tumors.
本文综述了细胞毒性药物在成人高级别胶质瘤中的单药试验。在脑肿瘤患者中测试这些药物的基本原理各不相同，本文对此进行了讨论。评估反应的标准也各不相同，从对临床改善的主观评估（影像学评估稳定）到用于实体瘤的相同客观反应标准。专门为脑肿瘤设计的药物试验，如AZQ和螺旋莫司汀，结果令人失望。在新型药物的早期试验中看到了令人鼓舞的结果，这些结果有待在更大规模的试验中得到证实，但有望改善目前原发性脑肿瘤化疗令人失望的结果。
